Borthwick Kathleen 4
4 · Passage BIO, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2024-02-13$0.97/sh−1,470$1,426→ 28,466 total - Exercise/Conversion
Restricted Stock Unit
2024-02-10−4,000→ 8,000 total→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2024-02-10+4,000→ 29,936 total
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F3]1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.